27022-97-5 Usage
General Description
2,5-DIMETHYL-3-NITROBENZOIC ACID is a chemical compound with the molecular formula C9H9NO4. It belongs to the class of benzoic acids, containing a nitro group and two methyl groups attached to the benzene ring. 2,5-DIMETHYL-3-NITROBENZOIC ACID is used as a synthetic intermediate in the production of pharmaceuticals and agrochemicals. It is also employed in the preparation of dyes and pigments, as well as in organic synthesis. Additionally, 2,5-DIMETHYL-3-NITROBENZOIC ACID has potential applications in the field of materials science and polymers. It is important to handle this chemical with care, as it may pose health hazards if not used properly.
Check Digit Verification of cas no
The CAS Registry Mumber 27022-97-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,0,2 and 2 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 27022-97:
(7*2)+(6*7)+(5*0)+(4*2)+(3*2)+(2*9)+(1*7)=95
95 % 10 = 5
So 27022-97-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H9NO4/c1-5-3-7(9(11)12)6(2)8(4-5)10(13)14/h3-4H,1-2H3,(H,11,12)
27022-97-5Relevant articles and documents
HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA
-
Page/Page column 38; 46; 47, (2018/03/28)
The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is -CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl- (C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or -ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.
